Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Definium Therapeutics, Inc.NASDAQ: DFTX
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q3 FY2026 selling, general & admin of $26.14M rose 77.9% year over year, behind the +86.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +17.3% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +26.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $26.14M-1.0% QoQ
- Last fiscal yearDec 2025
- $48.64M+26.0% YoY
- LTMSep 2026
- $84.34M+86.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +77.9% | -100.0% | -177.9 pp |
| 1 year | +26.0% | -100.0% | -126.0 pp |
| 3-year CAGR | +17.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 48.64M USD
- Year-over-year change
- +26.0%
- 4-year CAGR
- -4.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.64M | +26.0% |
| FY2024 | 2024-12-31 | 38.62M | -7.5% |
| FY2023 | 2023-12-31 | 41.74M | +38.4% |
| FY2022 | 2022-12-31 | 30.16M | -48.9% |
| FY2021 | 2021-12-31 | 59.07M | — |
Selling, General & Admin vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +86.2% is the 4th highest of 10, against a peer median of +37.9%.
- Over three fiscal years its annual growth of +17.3% compares with a peer median of +41.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.42B USD | +118480.6% | -4.1% | — | |
| LTM Jun 2026 | $712.67M USD | +55.0% | +53.0% | 91.8% | |
| LTM Sep 2026 | $117.61M USD | +115.1% | -0.3% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $84.34M USD | +86.2% | +17.3% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M USD | -17.1% | +24.5% | — |
| LTM Mar 2026 | $37.63M USD | +164.2% | +95.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M USD | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $23.07M USD | +35.6% | +29.0% | — | |
| LTM Mar 2026 | $21.89M USD | -3.6% | +59.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M USD | — | +110.6% | — |
| FY2025 | A$5.48M AUD | +15.1% | -0.2% | 100.8% | |
| Peer median (excluding DFTX) | — | +37.9% | +41.0% | 100.8% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 3.16M | 527K | 0 |
| Gross Profit | 0 | 0 | (3.16M) | (527K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 34.79M | 36.17M | 48.96M | 65.3M | 117.67M |
| Selling, General & Admin | 59.07M | 30.16M | 41.74M | 38.62M | 48.64M |
| Operating Expenses | 93.85M | 66.33M | 90.7M | 103.39M | 166.31M |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| EBITDA | (91.22M) | (52.12M) | (92.57M) | (105.87M) | (178.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (93.85M) | (66.33M) | (93.87M) | (103.92M) | (166.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.5M | 5.58M | 11.56M | 10.96M |
| Interest Expense | 359K | 1.5M | 920K | 2.28M | 5.48M |
| Other Income / Expenses | (339K) | 9.54M | (1.87M) | (4.76M) | (17.48M) |
| Income Before Tax | (94.19M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.16M) | 0 | 0 | 0 | 0 |
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.40) | (1.53) | (2.44) | (1.54) | (2.06) |
| EPS (Diluted) | (3.40) | (1.53) | (2.44) | (0.15) | (2.06) |
| Weighted Avg Shares | 27.38M | 30.86M | 39.16M | 70.46M | 89.33M |
| Weighted Avg Shares (Diluted) | 27.38M | 30.86M | 39.16M | 704.61M | 89.33M |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.